BACKGROUND: There are data suggesting a link between proton pump inhibitor (PPI) use and the development of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites; however, these data are controversial. OBJECTIVE: To assess whether the use of PPIs in cirrhotic patients with ascites is associated with an increased risk for SBP. METHODS: A retrospective case-control study (June 2004 to June 2010) was conducted at the Centre Hospitalier de l'Université de Montréal in Montreal, Quebec. Fifty-one cirrhotic patients admitted with paracentesis-proven SBP (≥250 neutrophils/mm3), occurring within seven days of hospital admission, met the inclusion criteria. These patients were matched 1:2 (for age, Child-Pugh class and year of admission) with 102 comparable cirrhotic patients with ascites who were admitted for conditions other than SBP. RESULTS: Patients with SBP had a significantly higher rate of pre-hospital PPI use (60.8%) compared with cirrhotic patients without SBP (42.2%; P=0.03). On multivariate analysis, PPI use was the only factor independently associated with SBP (OR 2.09 [95% CI 1.04 to 4.23]; P=0.04). Thirty-five (35%) patients in both groups had no documented indication for PPI use in their charts. Forty-five percent of the remaining cirrhotic patients with SBP had an inappropriate indication, as defined in the protocol, for PPI use compared with 25% of controls. CONCLUSIONS: Cirrhotic patients with SBP were twice as likely to have taken PPIs than patients without SBP. These findings reinforce the association between PPI use and SBP observed in other studies. A high percentage of cirrhotic patients were taking a PPI without any documented indication.
BACKGROUND: There are data suggesting a link between proton pump inhibitor (PPI) use and the development of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites; however, these data are controversial. OBJECTIVE: To assess whether the use of PPIs in cirrhotic patients with ascites is associated with an increased risk for SBP. METHODS: A retrospective case-control study (June 2004 to June 2010) was conducted at the Centre Hospitalier de l'Université de Montréal in Montreal, Quebec. Fifty-one cirrhotic patients admitted with paracentesis-proven SBP (≥250 neutrophils/mm3), occurring within seven days of hospital admission, met the inclusion criteria. These patients were matched 1:2 (for age, Child-Pugh class and year of admission) with 102 comparable cirrhotic patients with ascites who were admitted for conditions other than SBP. RESULTS:Patients with SBP had a significantly higher rate of pre-hospital PPI use (60.8%) compared with cirrhotic patients without SBP (42.2%; P=0.03). On multivariate analysis, PPI use was the only factor independently associated with SBP (OR 2.09 [95% CI 1.04 to 4.23]; P=0.04). Thirty-five (35%) patients in both groups had no documented indication for PPI use in their charts. Forty-five percent of the remaining cirrhotic patients with SBP had an inappropriate indication, as defined in the protocol, for PPI use compared with 25% of controls. CONCLUSIONS: Cirrhotic patients with SBP were twice as likely to have taken PPIs than patients without SBP. These findings reinforce the association between PPI use and SBP observed in other studies. A high percentage of cirrhotic patients were taking a PPI without any documented indication.
Authors: Lotte G van Vlerken; Ellen J Huisman; Bart van Hoek; Willem Renooij; Felix W M de Rooij; Peter D Siersema; Karel J van Erpecum Journal: Eur J Clin Invest Date: 2012-01-31 Impact factor: 4.686
Authors: Francesca Lodato; Francesco Azzaroli; Maria Di Girolamo; Valentina Feletti; Paolo Cecinato; Andrea Lisotti; Davide Festi; Enrico Roda; Giuseppe Mazzella Journal: World J Gastroenterol Date: 2008-05-21 Impact factor: 5.742
Authors: Marie de Vos; Bénédicte De Vroey; Béatrice Garcia Garcia; Clothilde Roy; François Kidd; Jean Henrion; Pierre Deltenre Journal: Liver Int Date: 2013-06-03 Impact factor: 5.828
Authors: Jasmohan S Bajaj; Yelena Zadvornova; Douglas M Heuman; Muhammad Hafeezullah; Raymond G Hoffmann; Arun J Sanyal; Kia Saeian Journal: Am J Gastroenterol Date: 2009-03-31 Impact factor: 10.864
Authors: Seong Jun Hwang; Dong Hyeon Lee; Seong-Joon Koh; Ji Won Kim; Hyun Sun Park; Byeong Gwan Kim; Kook Lae Lee Journal: Turk J Gastroenterol Date: 2022-01 Impact factor: 1.555
Authors: Suelen A S Miozzo; Jorge A John; Marcelo C Appel-da-Silva; Isabella A Dossin; Cristiane V Tovo; Angelo A Mattos Journal: World J Hepatol Date: 2017-12-18
Authors: David A Johnson; Philip O Katz; David Armstrong; Henry Cohen; Brendan C Delaney; Colin W Howden; Peter Katelaris; Radu I Tutuian; Donald O Castell Journal: Drugs Date: 2017-04 Impact factor: 9.546